Yoav Golan

Biography

Dr. Golan is an attending physician at the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, Boston and an Associate Professor of Medicine at Tufts University School of Medicine. Dr. Golan is a graduate of the Hadassah School of Medicine at the Hebrew University in Jerusalem, Israel. He completed a medicine residency and Infectious Diseases fellowship at the Tel Aviv Sourasky Medical Center, followed by a transplant ID fellowship and masters in statistics and modelling at Tufts University School of Medicine. His research focuses on hospital-acquired infections with emphasis on ICU infections, the impact of antibiotic resistance on outcomes, patient risk stratification, and development of early culture-independent treatment strategies. Over the past seven years, Dr. Golan’s research has focused on C. difficile infections as well as MRSA and invasive Candidiasis. He is particularly interested in recurrent disease and the effectiveness and affordability of new treatment strategies when stratified by patients’ risk of recurrence. Dr. Golan has been involved in the development of multiple anti-infectives, including, fidaxomicin, surotomycin and bezlotuximab. He is the author of numerous manuscripts and several book chapters. Dr. Golan is an attending physician at the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, Boston and an Associate Professor of Medicine at Tufts University School of Medicine. Dr. Golan is a graduate of the Hadassah School of Medicine at the Hebrew University in Jerusalem, Israel. He completed a medicine residency and Infectious Diseases fellowship at the Tel Aviv Sourasky Medical Center, followed by a transplant ID fellowship and masters in statistics and modelling at Tufts University School of Medicine. His research focuses on hospital-acquired infections with emphasis on ICU infections, the impact of antibiotic resistance on outcomes, patient risk stratification, and development of early culture-independent treatment strategies. Over the past seven years, Dr. Golan’s research has focused on C. difficile infections as well as MRSA and invasive Candidiasis. He is particularly interested in recurrent disease and the effectiveness and affordability of new treatment strategies when stratified by patients’ risk of recurrence. Dr. Golan has been involved in the development of multiple anti-infectives, including, fidaxomicin, surotomycin and bezlotuximab. He is the author of numerous manuscripts and several book chapters.

Research Interest

Clinical Pharmacy  Pharmaceutical Administration Medicinal Chemistry